Inspira™ Technologies OXY B.H.N. Ltd., based in Ra'anana, Israel, revealed groundbreaking news on September 11, 2025. The company, listed on NASDAQ as IINN, known for its innovative life-support and diagnostic technologies, shared a major milestone regarding its HYLA blood sensor. The sensor demonstrated an impressive 97.35% accuracy rate during the latest round of performance testing. These results are crucial as they will bolster the Company's submission to the U.S. Food and Drug Administration for approval. This achievement marks a substantial improvement from earlier data disclosed during a clinical study on March 4, 2025.